All News
In the CLOSE-UP study of UPA in RA
- 61% in remission with responses sustained to 24 mo
- Benefit consistent irrespective of prior DMARD use
- No new safety signals
@RheumNow #ACR25 Abstract#2281
Jiha Lee JihaRheum ( View Tweet)
Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics.
@RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d
Jiha Lee JihaRheum ( View Tweet)
Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is
⬇️rates of PulHPN (OR 0.79)
⬇️all-cause mortality (0.49)
⬇️hospitalizations (OR 0.56)
⬇️LN (OR 0.4)
vs non-SGLT2i users(p<0.001)
Impt role of SGLT2i as adjunct tx
#ACR25 @RheumNow Abs2438 https://t.co/NQJTzQwRCt
sheila RHEUMarampa ( View Tweet)
New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-clinical synovitis. Predicting who will develop RA is difficult, and there is a need for reliable biologic tools. Focusing on high-risk patients could https://t.co/SPOP7f0t7y
Dr. John Cush RheumNow ( View Tweet)
CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Punjadath et al. Predictors of progression palindromic rheumatism to RA. 30 patients. 47% progressed to RA. Total number of joints involved, RF, CRP predicted progression univariate. Only total joints significant in mutlivariate but underpowered. @RheumNow #ACR25 Abstr#2261 https://t.co/FtVKdGtEr9
Richard Conway RichardPAConway ( View Tweet)
Can fiber make methotrexate work better? (LB15)
In a placebo-controlled Superfibers RCT, inulin 12 g/day improved EULAR response & Th17/Treg ratio in RA among MTX users.
@RheumNow #ACR25 https://t.co/awMRNloNw5
Jiha Lee JihaRheum ( View Tweet)
Interesting study evaluating the "CALLY" index (serum albumin × lymphocyte count / CRP / 10,000) for predicing mortality in AAV
I typically dislike these because (1) they are often cumbersome to calculate & (2) they often perform poorly
This one piqued my interest; pretty https://t.co/ziroQOH5Cq
Mike Putman EBRheum ( View Tweet)
RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck)
Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw
Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪
@RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k
Links:
Mike Putman EBRheum ( View Tweet)
Late Breaker: Observational study of MEPO in EGPA
375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care
Smallish event #'s & lots of p values... also, what about the vasculitis?!?
#ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF
Links:
Mike Putman EBRheum ( View Tweet)
Semaglutide isn’t just for weight loss?
In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls.
GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism.
@RheumNow #ACR25 Abstract#2286
Jiha Lee JihaRheum ( View Tweet)
Adding social risk factors to the mix
Abstract 1917: WashU Rheumatology examined SRF screening in the clinic
🔹 50% screened once; 1/3 screened > 1
🔹 Core SRFs (finance, transport, housing, food) relatively stable
🔹 Biggest change over time: stress
@RheumNow #ACR25 https://t.co/oKlwMZ77nB
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
The CAR T engine doesn’t stop! LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥 ✅ Low AEs (mostly Gr 1–2 CRS, hematologic) 💪 Robust efficacy in lupus nephritis 🔄 Deep B-cell depletion → naïve B-cell repopulation @RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Effect of air pollution in RA
Prospective cohort 1000+pts w/ 12000+ visits
Higher levels of pollution
& specific size of particles PM25
asso w/
-10% higher odd of flare
-Higher DAS CRP and CDAI
Now the interesting pattern:
PM25 exposure increases 3 weeks before flares https://t.co/MOskJzk05g
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
CD19 counts during RTX maintenance therapy do NOT perform well in assessing the risk of relapse
Interestingly, only younger age was associated with relapse in this retrospective study
@RheumNow #ACR25 Abst 1766 https://t.co/crsFKJ0LnP
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Can AI predict who stops their RA meds?
In older adults on b/tsDMARDs, interpretable ML found frailty, comorbidity & age top the list for nonadherence risk.
@RheumNow #ACR25 Abstract#2287
Jiha Lee JihaRheum ( View Tweet)
Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO
Richard Conway RichardPAConway ( View Tweet)
In DISCOVER-2, male PsA patients had greater radiographic progression than females despite similar baseline scores. Early joint response (W8 cDAPSA LDA) was linked to less progression more strongly in men. Highlights the sex differences in PsA outcomes. Abstract#2345 @RheumNow https://t.co/zIo59FYPVg
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Macedo et al. Increasing exercise improved QoL in axSpA. Mobility limitation and obesity worsened it. At least to some degree these effects appear independent. @RheumNow #ACR25 Abstr#2326 https://t.co/Ei4cKTNHyn
Richard Conway RichardPAConway ( View Tweet)
A prediction model for RA-ILD in RA pts: is it possible?
Not quite yet!
Veterans Affairs RA registry 2700+ pts
5% of prevalent ILD
Associated w/
-GDF-15
-Pentraxin 3
No prediction for Incident disease
Needs more work to understand implications for practice
@RheumNow #ACR25 https://t.co/CmW72nybcQ
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
